Bakshi $4\mathrm{.}9$: Many With bacteria becoming resistant to antibiotics, there is an urgent need to develop new antibiotics. However, most drug companies are not working in this area because new antibiotics are used only after older ones stop working. This does not allow companies to make money, even though this approach is better for public health. What is the economic externality or tragedy of the commons in this situation? Suggest approaches that could address this problem.